Ondansetron Wockhardt Uk (Ondansetron Hydrochloride Dihydrate)

Ondansetron selectively blocks serotonin (5‑HT3) receptors in the gastrointestinal tract and the brain’s chemoreceptor trigger zone. By inhibiting serotonin binding, it interrupts the neural pathway that triggers the vomiting reflex, providing relief from nausea.

The prescribed dose of ondansetron is determined by the treating clinician based on the patient’s age, weight, the type of emetogenic stimulus and clinical guidelines. Healthcare professionals set the appropriate regimen for each individual case.

Ondansetron should be used in pregnancy only if the potential benefit outweighs any risk to the fetus, and it is classified as a Category B medication in many regions. While small amounts are excreted in breast milk, clinicians weigh the benefits against possible infant exposure before recommending use while breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering rapid onset and effective control of both acute and delayed nausea, especially from chemotherapy. Compared with dopamine antagonists such as metoclopramide, ondansetron has a lower risk of extrapyramidal side effects but requires attention to cardiac QT interval monitoring.

Store the tablets at temperatures below 25 °C, in the original container, protected from moisture, heat and direct sunlight. Maintaining these conditions preserves the product’s potency and stability throughout its shelf life.

Ondansetron tablets are taken orally with water, usually 30 minutes before the emetogenic stimulus (e.g., chemotherapy infusion) and may be repeated according to the prescriber’s schedule. Swallow the tablet whole; do not crush or chew unless directed by a healthcare professional.

The most serious adverse events include QT interval prolongation, which can lead to potentially life‑threatening arrhythmias, and severe allergic reactions such as anaphylaxis. Patients should be monitored for cardiac symptoms and any signs of hypersensitivity during treatment.

Ondansetron is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and in individuals taking apomorphine. Caution is also advised for patients with congenital long QT syndrome or significant electrolyte disturbances.